Reata Pharmaceuticals Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Pharmaceuticals

• Sub-sector

  Health Care

• Capitalization (millions of $)

  6566.4

• Ticker

  RETA.O

• ISIN

  US75615P1030

• IPO date

• Availability on Russian exchanges

  No

• Reporting for

  2023-08-08

• Date fact. publication of reports

  2023-06-30

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.